CSO Christopher Loose resigns; severance includes equity acceleration tied to Korro merger

Korro Bio, Inc.

Christopher Loose resigned as Chief Scientific Officer effective July 28, 2023.
Severance includes 12 months base salary, COBRA coverage, and $201,744.35 target bonus.
Unvested time-based equity awards accelerate only if proposed merger with Korro Bio closes by Dec 31, 2023.
Separation agreement includes standard release of claims and non-disparagement obligations.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Loose

Chief Scientific Officer

KRRO · Korro Bio, Inc.

Effective: 2023-07-28
Filed: July 31, 2023, 7:59 PM ET

On July 28, 2023, Christopher Loose, Ph.D., notified Frequency Therapeutics, Inc. (the “Company”) that he would be resigning from his position as Chief Scientific Officer of the Company, effective July 28, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Loose resigned as Chief Scientific Officer at Korro Bio, Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

On July 28, 2023, Christopher Loose, Ph.D., notified Frequency Therapeutics, Inc. (the “Company”) that he would be resigning from his position as Chief Scientific Officer of the Company, effective July 28, 2023

View on SEC.gov

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-199108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.